These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24404903)

  • 21. Cardio-renal syndrome type 4: epidemiology, pathophysiology and treatment.
    House AA
    Semin Nephrol; 2012 Jan; 32(1):40-8. PubMed ID: 22365161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a cardiomyopathy of obesity?
    Owan T; Litwin SE
    Curr Heart Fail Rep; 2007 Dec; 4(4):221-8. PubMed ID: 18221619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hemodialysis cardiomyopathy or uremic cardiomyopathy?].
    Dongradi G; Fendler JP
    Nouv Presse Med; 1977 Jun; 6(23):2035-6. PubMed ID: 887400
    [No Abstract]   [Full Text] [Related]  

  • 24. [Risk factors for myocardial remodeling at stage II-IV of chronic kidney disease].
    Rudenko TE; Kutyrina IM; Shvetsov MIu
    Ter Arkh; 2012; 84(6):21-6. PubMed ID: 22997913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are we overestimating left ventricular abnormalities in end-stage renal disease?
    Mark PB; Patel RK; Jardine AG
    Nephrol Dial Transplant; 2007 Jul; 22(7):1815-9. PubMed ID: 17438003
    [No Abstract]   [Full Text] [Related]  

  • 26. A new porcine model of hypertensive cardiomyopathy: a helpful tool to explore the HFpEF mystique.
    Hu K; Ertl G
    Am J Physiol Heart Circ Physiol; 2015 Nov; 309(9):H1390-1. PubMed ID: 26386114
    [No Abstract]   [Full Text] [Related]  

  • 27. Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?
    Smith K; Semple D; Bhandari S; Seymour AM
    Eur J Heart Fail; 2009 Aug; 11(8):732-8. PubMed ID: 19633100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease .
    Akaishi M; Hiroe M; Hada Y; Suzuki M; Tsubakihara Y; Akizawa T;
    J Cardiol; 2013 Oct; 62(4):249-56. PubMed ID: 23787155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular Disease in Children and Adolescents With Chronic Kidney Disease.
    Weaver DJ; Mitsnefes M
    Semin Nephrol; 2018 Nov; 38(6):559-569. PubMed ID: 30413251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney].
    Tomilina NA; Storozhakov GI; Gendlin GE; Badaeva SV; Zhidkova DA; Kim IG; Borisovskaia SV; Loss KE; Fedorova ND
    Ter Arkh; 2007; 79(6):34-40. PubMed ID: 17684964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac Metabolism in Heart Failure and Implications for Uremic Cardiomyopathy.
    Nguyen TD; Schulze PC
    Circ Res; 2023 Apr; 132(8):1034-1049. PubMed ID: 37053280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Echocardiography in nephrology].
    Di Lullo L; Granata A; Logias F; Fiorini F; D'Amelio A; Zamboli P; Malaguti M; Santoboni A; Floccari F
    G Ital Nefrol; 2012; 29 Suppl 57():S74-82. PubMed ID: 23229532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac metabolic remodelling in chronic kidney disease.
    Patel N; Yaqoob MM; Aksentijevic D
    Nat Rev Nephrol; 2022 Aug; 18(8):524-537. PubMed ID: 35637381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.
    Law JP; Price AM; Pickup L; Radhakrishnan A; Weston C; Jones AM; McGettrick HM; Chua W; Steeds RP; Fabritz L; Kirchhof P; Pavlovic D; Townend JN; Ferro CJ
    J Am Heart Assoc; 2020 Apr; 9(7):e016041. PubMed ID: 32212912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.
    Wang X; Liu J; Drummond CA; Shapiro JI
    Expert Opin Ther Targets; 2017 May; 21(5):531-541. PubMed ID: 28338377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiac alterations caused by renal failure].
    Schannwell CM
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():69-71. PubMed ID: 16802524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives.
    Dobre MA; Ahlawat S; Schelling JR
    Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):203-211. PubMed ID: 38193308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy.
    Maron MS; Zenovich AG; Casey SA; Link MS; Udelson JE; Aeppli DM; Maron BJ
    Am J Cardiol; 2005 Jun; 95(11):1329-33. PubMed ID: 15904638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of uremic cardiomyopathy for the practicing clinician: an educational review.
    Hiraiwa H; Kasugai D; Okumura T; Murohara T
    Heart Fail Rev; 2023 Sep; 28(5):1129-1139. PubMed ID: 37173614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.